Sepracor-Looks very promising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	7/31/2007 2:19:56 AM
	of 10280

Sepracor "neutral," target price reduced - update Monday, July 30, 2007 12:10:08 PM ET UBS NEW YORK, July 30 (newratings.com) - Analysts at UBS maintain their "neutral" rating on Sepracor (SEPR.NAS), while reducing their estimates for the company. The target price has been reduced from $47.00 to $28.50. In a research note published this morning, the analysts mention that the company has posted weak 2Q07 results, with revenues significantly short of the estimates and the consensus. The performance of Sepracor's products was lower than expected during the quarter, the analysts say. Although Sepracor is reorganizing its commercial functions to improve its productivity, the visibility into the company's future product growth is limited, UBS adds. The company has reduced its EPS guidance for 2007 to $1.00-$1.30. The EPS estimates for 2007 and 2008 have been reduced from $2.05 to $0.57 and from $2.95 to $1.57, respectively. [As in "We really have no idea, so let's continue to rate them neutral"].

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next